| Title |
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2013
|
| DOI | 10.1007/s00280-013-2151-8 |
| Pubmed ID | |
| Authors |
Masashi Kanai, Yoshihiko Otsuka, Kazunori Otsuka, Maremi Sato, Takafumi Nishimura, Yukiko Mori, Michiya Kawaguchi, Etsuro Hatano, Yuzo Kodama, Shigemi Matsumoto, Yoshiki Murakami, Atsushi Imaizumi, Tsutomu Chiba, Jun Nishihira, Hiroyuki Shibata |
| Abstract |
A growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major obstacle for its clinical application. To overcome this problem, we developed a new form of curcumin (Theracurmin) and reported high plasma curcumin levels could be safely achieved after a single administration of Theracurmin in healthy volunteers. In this study, we aimed to evaluate the safety of repetitive administration of Theracurmin in cancer patients. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Spain | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 202 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | <1% |
| Brazil | 1 | <1% |
| Unknown | 199 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 14% |
| Student > Master | 24 | 12% |
| Student > Bachelor | 21 | 10% |
| Student > Ph. D. Student | 19 | 9% |
| Other | 17 | 8% |
| Other | 33 | 16% |
| Unknown | 59 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 21% |
| Biochemistry, Genetics and Molecular Biology | 20 | 10% |
| Agricultural and Biological Sciences | 16 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 8% |
| Chemistry | 8 | 4% |
| Other | 33 | 16% |
| Unknown | 66 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2021.
All research outputs
#3,289,397
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#109
of 2,501 outputs
Outputs of similar age
#27,707
of 201,285 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 37 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,285 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.